Pragmatic Clinical Trial Resources-The need for pragmatic, affordable, and practice-changing real-life clinical trials in oncology

The need for pragmatic, affordable, and practice-changing real-life clinical trials in oncology

Pdf Summary

The article argues that modern oncology clinical trials have become increasingly complex, expensive, and poorly generalisable to real-world patients and care settings. Precision oncology and advanced biotherapies have driven more restrictive eligibility criteria, extensive molecular testing, and heavy regulatory and administrative burdens. As trials focus on narrower biomarker-defined subgroups, screening failures rise and many more sites are needed to recruit enough participants. Overly selective criteria also exclude typical patients—often older and with comorbidities—so results may not translate to everyday practice; for example, only about 30% of real-world lung cancer patients meet eligibility for randomized trials of novel drugs. Evidence suggests that relaxing some criteria could substantially increase eligibility with minimal impact on overall survival estimates.<br /><br />The authors also question the value delivered by many newly approved cancer drugs: a large share of approvals have relied on single-arm trials, and median absolute overall survival gains have been modest, while drug prices have risen dramatically. Meanwhile, trial data collection has exploded (millions of data points; much longer case report forms), even though only a small fraction of collected data relates to primary endpoints or appears in publications. Pivotal phase 3 trials can cost tens of millions of dollars, driven by extra testing, paperwork, and monitoring.<br /><br />To address these problems, the authors call for more pragmatic, affordable “real-life” oncology trials designed to inform decisions for patients, clinicians, and policymakers in routine settings, including low-resource regions. Such trials should use broad, representative eligibility; minimal extra procedures and essential data only; and endpoints that matter to patients—especially overall survival and quality of life—alongside societal cost–benefit considerations. They highlight examples where pragmatic trials enabled treatment de-escalation or showed efficacy with much lower drug doses, improving access. Because industry is unlikely to fund these studies, they advocate philanthropic, governmental, payer, and EU-level support to expand equitable, practice-changing research.

Keywords

oncology clinical trials complexity

pragmatic real-world cancer trials

restrictive eligibility criteria

precision oncology biomarkers

screening failures recruitment burden

generalizability to routine care

single-arm trial approvals

overall survival and quality of life endpoints

clinical trial data collection burden

cancer drug costs and value